Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents
Open Access
- 10 May 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 43 (6), 693-706
- https://doi.org/10.1007/s13318-018-0481-y
Abstract
The helicase-primase inhibitor amenamevir (ASP2151) is a novel therapeutic agent which has been approved for the treatment of herpes zoster. The present study examined the pharmacokinetic profile of amenamevir in rodents and compared it with data from the literature of past and current established therapies (acyclovir and valaciclovir) to provide additional data to facilitate drug discovery and proper drug use.Keywords
Funding Information
- Astellas Pharma
This publication has 25 references indexed in Scilit:
- Helicase-Primase as a Target of New Therapies for Herpes Simplex Virus InfectionsClinical Pharmacology & Therapeutics, 2014
- Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non‐linear effect model for the treatment of genital herpesClinical Pharmacology in Drug Development, 2014
- Pharmacokinetics and Pharmacodynamics of ASP2151, a Helicase-Primase Inhibitor, in a Murine Model of Herpes Simplex Virus InfectionAntimicrobial Agents and Chemotherapy, 2013
- Absorption: In Vivo Tests (Radiolabeled)Published by Springer Science and Business Media LLC ,2013
- Significance of Peptide Transporter 1 in the Intestinal Permeability of Valacyclovir in Wild-Type and PepT1 Knockout MiceDrug Metabolism and Disposition, 2012
- Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in ratsExperimental and Therapeutic Medicine, 2012
- ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2Journal of Antimicrobial Chemotherapy, 2010
- METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERSDrug Metabolism and Disposition, 2005
- Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humansAntimicrobial Agents and Chemotherapy, 1995
- Metabolic disposition of acyclovir in the guinea pig, rabbit, and monkeyThe American Journal of Medicine, 1982